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A
 
BSTRACT
Background:
 
Olopatadine hydrochloride is an anti-
allergic agent with histamine H
 
1
 
 receptor antagonistic
action. We investigated the effects of olopatadine on
passive anaphylaxis reaction- and compound 48/80-
induced conjunctivitis in rats.
 
Methods:
 
Allergic conjunctivitis was induced in rats
passively sensitized by injection of rat anti-ovalbumin
(anti-OVA) serum into the upper subconjunctiva of the
right eye, followed by intravenous administration of
the antigen and Evans blue dye. After 30 min, the
amount of dye leaking into the conjunctiva was meas-
ured. Non-allergic conjunctivitis was induced in rats by
injection of compound 48/80. Olopatadine or other
reference compounds were orally given 1 h before the
challenge.
 
Results:
 
The amount of dye leaking into the
conjunctiva following passive anaphylaxis was
significantly inhibited by oral administration of
0.01–1 mg/kg olopatadine and the ID
 
50
 
 value was
0.093 mg/kg. In the control group, pathological
examination revealed edema and lymphocyte infil-
tration in the conjunctiva and the palpebral skin.
Olopatadine, at 0.03 and 0.3 mg/kg, reduced the
grade of these pathological findings. The other
antiallergic drugs (1 mg/kg loratadine, 0.3 mg/kg
epinastine, 0.3 mg/kg cetiridine, 1 mg/kg ebastine,
30 mg/kg fexofenadine and 3 mg/kg chlorphe-
niramine), when administered orally, inhibited the
passive anaphylaxis reaction-induced vascular hyper-
permeability of the conjunctiva, as was the case with
olopatadine hydrochloride. Subconjunctival administra-
tion of compound 48/80 induced vascular hyper-
permeability, which is presumably mediated by
histamine release. Oral administration of 0.1 and
1 mg/kg olopatadine significantly inhibited the amount
of dye leakage.
 
Conclusion:
 
Orally administered olopatadine is
expected to improve allergic conjunctivitis.
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I
 
NTRODUCTION
 
Patients with allergic conjunctivitis suffer from itching,
redness, edema and tearing, accompanied by vascular
hyperpermeability in the conjunctiva. Allergic conjuncti-
vitis often occurs concomitantly with rhinitis in subjects
with seasonal allergy.
 
1
 
 Of the various mediators, hista-
mine plays a crucial role and, thus, antihistamine drugs
are used as first-line therapy for ocular and nasal
allergy.
Topical therapy has been the preferred treatment for
ocular allergic disease. Eye drops can be applied easily
and seldom lead to systemic side-effects. Moreover, the
physical presence of the drops themselves will have a
washout effect, helping to remove the inflammatory
mediators and, thereby, lessening some of the symptoms.
In contrast, topical treatment may also have some dis-
advantages. Although topical steroids are effective in
reducing the influx of inflammatory cells, they have little
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effect on mast cell mediator secretion and take several
days to achieve their maximal effect. Oral histamine H
 
1
 
receptor antagonists have been shown to be effective
against the allergy,
 
2
 
 although they are not always useful
because they sometimes exhibit some systemic side-
effects, such as sedation.
Olopatadine hydrochloride (Allelock
 
®
 
; Kyowa Hakko
Kogyo, Shizuoka, Japan) is an anti-allergic agent with
histamine H
 
1
 
 receptor antagonistic action
 
3,4
 
 that is indi-
cated for the treatment of the signs and symptoms of
allergic rhinitis, chronic urticaria, eczema dermatitis,
prurigo, pruritis cutaneous, psoriasis vulgaris and erythema
exsudativum multiforme. Olopatadine exhibits potent
antihistamine activity 
 
in vivo
 
 following its systemic
administration.
 
5
 
 In addition, a previous 
 
in vitro
 
 study has
demonstrated that olopatadine inhibits the release of
chemical mediators, such as thromboxane B
 
2
 
, peptide
leukotriene and tachykinin.
 
6–8
 
 Moreover, olopatadine
inhibits the anti-IgE antibody induced release of tumor
necrosis factor (TNF)-
 
α
 
 from human conjunctival mast
cells and, furthermore, decreases the anti-IgE mast cell
supernatant-induced upregulation of intercellular adhe-
sion molecule-1 (ICAM-1) on human conjunctival epi-
thelial cells.
 
9,10
 
 Olopatadine ophthalmic solution 0.1%
(w/v; Patanol
 
®
 
; Alcon Laboratories, Fort Woth, TX, USA)
has been approved for the treatment of the signs and
symptoms of allergic conjunctivitis.
Anti-allergic drugs are widely used for the treatment of
allergic conjunctivitis and there is considerable literature
about the clinical efficacy of anti-allergic drugs. In con-
trast, little work has been published on the effects of anti-
allergic drugs in experimental allergic conjunctivitis. The
present study was conducted to clarify the effects of orally
administered olopatadine on the passive anaphylaxis
reaction-induced vascular hyperpermeability of the con-
junctiva in a rat model of allergic conjunctivitis. We also
examined the effects of the other anti-allergic drugs
(loratadine, epinastine, fexofenadine, cetiridine, ebastine
and the classic antihistamine chlorpheniramine). Further-
more, we examined the effect of olopatadine on the vas-
cular hyperpermeability induced by compound 48/80.
 
M
 
ETHODS
 
Animals
 
Male Sprague-Dawley rats (5 weeks old) were pur-
chased from Charles River Japan (Kanagawa, Japan).
Experiments were conducted in accordance with the
Guiding Principles for the Care and Use of Laboratory
Animals, and the experimental protocol was approved
by the Committee for Animal Experiments in Kyowa
Hakko Kogyo. Rats were kept in a specific pathogen-free
animal facility at a temperature of 22–24
 
°
 
C, humidity of
50–60% and a 12 h light/dark cycle.
 
Materials
 
Olopatadine hydrochloride, loratadine, epinastine
hydrochloride, fexofenadine hydrochloride, cetirizine
hydrochloride and ebastine were synthesized or
extracted from commercially available tablets in our
institute. Sodium cromoglicate ophthalmic solution 2%
w/v (Intal
 
®
 
; disodium cromoglycate (DCSG)) was pur-
chased from Fujisawa Pharmaceutical (Osaka, Japan).
Chlorpheniramine maleate, ovalbumin (OVA; albumin,
chicken egg) and compound 48/80 were purchased
from Sigma Chemical (St Louis, MO, USA). Evans blue
was purchased from Aldrich (Milwaukee, WI, USA).
 
Bordetella pertussis
 
 inactive microorganism suspension
and formamide were purchased from Wako Pure Chem-
ical (Osaka, Japan). Olopatadine, epinastine, cetirizine
and chlorpheniramine were dissolved in distilled water.
Loratadine, fexofenadine and ebastine were suspended
in 0.5% w/v methylcellulose solution. All drugs were
administered orally at a volume of 1 mL/100 g body-
weight.
 
Antiserum
 
Rat antiserum to OVA was obtained according to the
method of Stotland and Share.
 
11
 
 Rats were sensitized by
injection of 0.6 mL saline containing OVA (1.5 mg),
alum (12 mg) and 6 
 
×
 
 10
 
9
 
 cells 
 
B. pertussis
 
 into the four
footpads. Five days later, the sensitization was boosted
by an intramuscular injection of 0.05 mL saline contain-
ing OVA (0.5 mg). A further 5 days later, whole blood
was collected from the abdominal aorta and serum was
stored at –80
 
°
 
C. The passive cutaneous anaphylaxis titer
in rats was 1 : 64.
 
Passive anaphylaxis reaction-induced vascular 
hyperpermeability in the rat conjunctiva
 
Rats were passively sensitized by diluted rat anti-OVA
serum (1 : 16) injected subconjunctivally into the right
eye. Forty-eight hours after passive sensitization, 5 mg
OVA dissolved in 1 mL of 0.5% w/v Evans blue solution
was injected intravenously. Thirty minutes after the chal-
lenge, rats were killed and the eyeballs and conjunctiva
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were removed and immersed in formamide at 45°C
overnight. The amount of dye in the extracted solution
was determined with a spectrophotometer (THERMO
maxTM; Molecular Devices, Sunnyvale, CA, USA) at
625 nm. Olopatadine and reference drugs were admin-
istered orally 1 h before antigen challenge. Disodium
cromoglycate (10 µL; 0.2 mg/site) was applied topically
in the eye 20 min before challenge. Vehicle (distilled
water or 0.5% w/v methylcellulose solution) was admin-
istered orally 1 h before the challenge as a control.
Histopathology
A passive anaphylaxis reaction was produced in the rat
conjunctiva, as noted above. The effects of 0.03 and
0.3 mg/kg olopatadine were examined. Thirty minutes
after challenge, rats were killed. The eyelids and eyeballs
were removed and fixed in neutral-buffered formalin and
then embedded in paraffin wax. Tissue sections for light
microscopic observation were stained with hematoxylin
and eosin. Preparations were observed under a light
microscope (BX60; Olympus Optical, Tokyo, Japan).
Pathological examination revealed edema and lympho-
cyte infiltration in the conjunctiva and the palpebral skin.
Fig. 1 Effects of orally administered olopatadine on passive
anaphylaxis reaction-induced vascular hyperpermeability of the
conjunctiva in rats. Animals were passively sensitized by the rat
anti-ovalbumin (OVA) serum or treated with saline (
 

 
). Forty-
eight hours after sensitization, a mixture of OVA and Evans blue
dye was injected intravenously. Thirty minutes after the chal-
lenge, each conjunctiva was isolated and the pigment was
extracted and quantified photometrically. Olopatadine was
administered orally 1 h before the challenge. Disodium cromo-
glycate (10 µ; ) was applied topically to the eye 20 min
before challenge. Distilled water was administered orally 1 h
before the challenge as a control (
 

 
). Data are the mean ± SEM
(n = 6). *P < 0.001 compared with control (Dunnett’s test);
†P < 0.001 compared with control (Student’s t-test).
Fig. 2 Photographs showing the effects of orally administered
olopatadine on passive  anaphylaxis reaction-induced conjuncti-
vitis in rats. Animals were passively sensitized by rat anti-ovalbumin
(OVA) or treated with saline  (non-sensitized). Forty-eight hours
after sensitization, 0.03 mg/kg olopatadine or distilled water
(control) was administered orally and then OVA solution was
injected intravenously. Thirty minutes after the challenge, the
conjunctiva and palpebral skin were isolated. Tissue  sections were
stained with hematoxylin and eosin. (a) Non-sensitized, (b) control
and (c) 0.03 mg/kg olopatadine. (Original  magnification ×
 
60.)
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The edema was graded as follows: –, no remarkable
abnormality; 
 
±
 
, very slight changes; +, slight changes;
++, moderate changes; and +++, severe changes.
 
Compound 48/80-induced vascular 
hyperpermeability in the rat conjunctiva
 
Rats were injected intravenously with 1 mL of 1% w/v
Evans blue dye. Immediately thereafter, each animal
was injected subconjunctivally with compound 48/80
(50 
 
µ
 
g/50 
 
µ
 
L) in the right eye. Thirty minutes after the
injection of compound 48/80, animals were killed and
hyperpermeability responses were quantitated as noted
above. Olopatadine was administered orally 1 h before
the injection of compound 48/80. Disodium cromog-
lycate (10 
 
µ
 
L) was applied topically to the eye 20 min
before the injection of compound 48/80. Vehicle (dis-
tilled water) was administered orally 1 h before the
injection and served as a control.
 
Data analysis
 
Data are presented as the mean 
 
±
 
 SEM. The 
 
F
 
-test,
followed by the Aspin–Welch test or Student’s 
 
t
 
-test, was
used for analysis of differences between two groups.
Multiple comparisons among treatment groups were
assessed by one-way analysis of variance, followed by
Dunnett’s test for ad hoc comparisons. 
 
P
 
 < 0.05 was
considered statistically significant. The ID
 
50
 
 value was
calculated by the probit method.
 
R
 
ESULTS
 
Effects of orally administered olopatadine on 
the passive anaphylaxis reaction-induced 
conjunctivitis
 
As shown in Fig. 1, the amount of dye leaking into the
conjunctiva was significantly increased in the control
group compared with the non-sensitized group. The
amount of dye leaking into the conjunctiva in the control
and non-sensitized groups was 14.8 
 
±
 
 0.6 and 3.4 
 
±
 
0.5 
 
µ
 
g, respectively. Orally administered olopatadine
(0.01–1 mg/kg) significantly inhibited dye leakage and
ID
 
50
 
 was 0.093 mg/kg. At 0.2 mg/site, DSCG signifi-
cantly inhibited dye leakage by 43.2%.
Pathological examination revealed edema and lym-
phocyte infiltration in the conjunctiva and the palpebral
skin in the control group (Fig. 2; Table 1). Olopatadine
(0.03 mg/kg) reduced both edema and lymphocyte
infiltration. No swelling or lymphocyte migration was
observed in rats treated with 0.3 mg/kg olopatadine.
 
Effects of orally administered loratadine, 
epinastine, fexofenadine, cetirizine and 
ebastine on the passive anaphylaxis 
reaction-induced vascular hyperpermeability 
of the conjunctiva
 
In another series of experiments, we examined the
effects of the anti-allergic drugs loratadine, epinastine,
 
Table 1
 
Effects of orally administered olopatadine on the morphology of the conjunctiva and palpebral skin in rats with passive
anaphylaxis reaction-induced conjunctivitis
Site Finding Grade No. animals 
Non-sensitized Control Olopatadine
Conjunctiva Edema in the submucosa – 6 1 5 6
 
±
 
1 1
+ 4
++
+++
Palpebral skin Edema in the dermis – 6 1 4 6
 
±
 
2
+ 3
++ 2
+++
 
Animals were passively sensitized by rat anti-ovalbumin (OVA) or treated with saline (non-sensitized). Forty-eight hours after sensitization, 0.03
or 0.3 mg/kg olopatadine or distilled water (control) was administered orally and then OVA solution was injected intravenously. Thirty minutes after
the challenge, the conjunctiva and palpebral skin were isolated. Tissue sections were stained with hematoxylin and eosin and graded as follows: –,
no remarkable abnormality; 
 
±
 
, very slight change; +, slight change; ++, moderate change; and +++, severe change. Six animals were examined
for each group.
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fexofenadine, cetiridine, ebastine and the classic anti-
histaminic chlorpheniramine on the passive anaphylaxis-
induced vascular hyperpermeability of the conjunctiva.
As shown in Fig. 3, the amount of dye leaking into the
conjunctiva was significantly increased in the control
group compared with the non-sensitized group. Lora-
tadine (at doses of 1 mg/kg and more) significantly
inhibited dye leakage and the ID50 for loratadine was
2.1 mg/kg. Epinastine (at doses of 0.3 mg/kg and
more) significantly inhibited dye leakage and the ID50
for epinastine was 9.7 mg/kg. Cetiridine (at doses of
0.3 mg/kg and more) significantly inhibited dye leakage
and the ID50 for cetridine was 3.3 mg/kg. Ebastine (at
doses of 1 mg/kg and more) significantly inhibited dye
leakage and the ID50 for ebastine was 5.2 mg/kg.
Fexofenadine (30 mg/kg) significantly inhibited dye
leakage. Chlorpheniramine (at doses of 3 mg/kg and
more) significantly inhibited dye leakage and the ID50 for
chlorpheniramine was 12.4 mg/kg.
Effects of orally administered olopatadine on 
the compound 48/80-induced vascular 
hyperpermeability of the conjunctiva
As an index of antihistamine activity, we determined the
effect of orally administered olopatadine on the vascular
hyperpermeability response to compound 48/80. As
shown in Fig. 4, injection of compound 48/80 signifi-
cantly increased the amount of dye leaking into the
conjunctiva compared with the amount of dye leaking
out following saline injection. The amount of dye leaking
in the control and non-sensitized groups was 17.3 ± 2.0
Fig. 3 Effects of loratadine, epinastine, fexofenadine, ceti-
rizine, ebastine and chlorpheniramine on passive anaphylaxis
reaction-induced vascular hyperpermeability of the conjunctivi-
tis in rats. Animals were passively sensitized by the rat anti-
ovalbumin (OVA) serum. Forty-eight hours after sensitization, a
mixture of OVA and Evans blue dye was injected intravenously.
Thirty minutes after the challenge, each conjunctiva was isolat-
ed and the pigment was extracted and quantified photometri-
cally. Various drugs and distilled water or 5% w/v
methycellulose (
 

 
) were administered orally 1 h before the
challenge. Data are the mean ± SEM (n = 6). *P < 0.05,
**P < 0.01, ***P < 0.001 compared with control (Dunnett’s
test); †P < 0.05 compared with control (Steel test).
Fig. 4 Effects of orally administered olopatadine on com-
pound 48/80-induced vascular hyperpermeability of the
conjunctiva in rats. Animals were treated with 50 µ
 
L of 0.1% w/v
compound 48/80 or saline (
 

 
) and Evans blue dye was injected
intravenously. Thirty minutes after the injection, each con-
junctiva was isolated and the dye was extracted and quantified
photometrically. Various doses of  olopatadine were adminis-
tered orally 1 h before the challenge. Disodium cromoglycate
(10 µ
 
L; ) was applied topically in both  eyes 20 min before
the challenge. Distilled water was orally administered 1 h before
the challenge as a control (
 
). Data are the  mean ± SEM
(n = 6). *P < 0.05 compared with control (Steel test);
†P < 0.05, ††P < 0.01 compared with control (Aspin-Welch
test).
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and 4.7 ± 0.6 µg, respectively. Olopatadine (0.1 and
1 mg/kg) significantly inhibited dye leakage by 49.7
and 63.0%, respectively. At 0.2 mg/site, DSCG also
significantly inhibited dye leakage by 42.2%.
DISCUSSION
The present study demonstrated that orally administered
olopatadine inhibited the amount of dye leaking into the
conjunctiva following passive anaphylaxis or compound
48/80 in rats. Our present results are in accordance
with previous observations that olopatadine inhibits anti-
gen- or histamine-induced experimental conjunctivitis in
guinea pigs, as was examined using a scoring system.12
Similarly, the other histamine H1 receptor antagonists
also inhibited the passive anaphylaxis-induced dye
leakage into the conjunctiva, although the potencies
were somewhat less than that of olopatadine. Moreover,
the present pathological examination clarified that
olopatadine reduced the grade of edema in the con-
junctiva and palpebral skin, as well as lymphocyte
infiltration. The present results suggest that orally admin-
istered olopatadine is effective for the treatment of
conjunctivitis.
Allergic conjunctivitis frequently occurs concomitantly
with rhinitis in subjects with seasonal allergy. Currently,
anti-allergic drugs with histamine H1 antagonistic action
are prescribed for ocular and nasal allergic diseases.
Olopatadine ophthalmic solution (eye drops) has been
shown to be effective for the treatment of the signs and
symptoms of allergic conjunctivitis.13,14 Indeed, although
topical therapy is the preferred treatment for ocular
allergy, it cannot adequately control the signs and
symptoms associated with multiple target organ hyper-
sensitivity, including allergic rhinitis. Thus, systemic anti-
allergic therapy may be of additional benefit in patients
receiving a local therapy. The results of the present study
indicate amelioration of the conjunctivitis by orally
administered olopatadine, suggesting that the dose of
this agent may be effective against conjunctivitis occur-
ring concomitantly with rhinitis.
In the present study, we used a rat model of allergic
conjunctivitis15,16 and conjunctival vascular hyper-
permeability17 that is sensitive to histamine H1 antago-
nists. Thus, it is likely that the effectiveness of olopatadine
in the conjunctivitis model used in the present study
involves histamine H1 receptor blockade, because this
drug exhibits potent histamine H1 antagonistic activity.2–5
Moreover, the inhibitory effect of olopatadine on hista-
mine release may have played a role, because this drug
has been shown to inhibit histamine release from mast
cells.18 Accordingly, DSCG ophthalmic solution, an
inhibitor of histamine release, also possessed an inhibi-
tory effect on vascular hyperpermeability. Moreover, in
the present study, olopatadine inhibited compound
48/80-induced vascular hyperpermeability. Compound
48/80 is known to cause histamine release from rat
conjunctival mast cells,19,20 which possibly contributes to
vascular hyperpermeability. These observations suggest
that the amelioration by olopatadine of the conjunctivitis
is mainly mediated by its suppressive effect on histamine
action (i.e. H1 rreceptor antagonistic action and/or an
inhibitory action on histamine release).
In addition to the suppressive effect on histamine
action, some other mechanisms may be involved in
the amelioration of the conjunctivitis by olopatadine.
This notion is supported by the clinical observation
that olopatadine ophthalmic solution showed some
advantage over the histamine H1 receptor antagonist
ketotifen.13,14 It has been reported that the levels of hista-
mine and substance P in tears of patients with allergic
conjunctivitis are elevated.21,22 Thus, the increased level
of substance P, in addition to histamine, in tears may
contribute to the pathogenesis and severity of ocular
allergic diseases. Accordingly, the inhibition of tachykinin
release by olopatadine8 may be involved in the inhibition
f conjunctivitis by this drug. In contrast, olopatadine
inhibited the release of TNF-α from human conjunctival
mast cells and, furthermore, it decreased the upregula-
tion of ICAM-1 on human conjunctival epithelial cells,9,10
suggesting that the reduced TNF-α release and ICAM-1
upregulation may also have played roles in the efficacy of
olopatadine. Taken together, the results indicate that it is
likely that olopatadine modulates the ocular allergic
reaction via interference with multiple signaling pathways
in the conjunctiva. Further studies are needed to eluci-
date the effect of olopatadine on various chemical medi-
ators in the conjunctiva and tears.
In conclusion, orally administered olopatadine was
demonstrated to inhibit the passive anaphylaxis reaction-
or compound 48/80-induced vascular permeability,
probably mainly via its histamine suppressive action.
Olopatadine was more potent than the other anti-allergic
drugs in the passive anaphylaxis reaction-induced vas-
cular hyperpermeability. Thus, it is expected that oral
administration of olopatadine is effective for the treat-
ment of conjunctivitis.
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